LumiraDx Limited (LMDX) News

LumiraDx Limited (LMDX): $1.69

-0.02 (-1.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter LMDX News Items

LMDX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest LMDX News From Around the Web

Below are the latest news stories about LumiraDx Ltd that investors may wish to consider to help them evaluate LMDX as an investment opportunity.

Wall Street Analysts Believe LumiraDx Limited (LMDX) Could Rally 54%: Here's is How to Trade

The mean of analysts' price targets for LumiraDx Limited (LMDX) points to a 53.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | January 25, 2022

Is Community Health Systems (CYH) Outperforming Other Medical Stocks This Year?

Here is how Community Health Systems (CYH) and LumiraDx Limited (LMDX) have performed compared to their sector so far this year.

Yahoo | January 25, 2022

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of COVID-19 variants show its SARS-CoV-2 Antigen test detects the Omicron Variant. In-house wet testing with live Omicron virus demonstrated that the LumiraDx SARS-CoV-2 Antigen test detects the Omicron variant with comparable sensitivity to other variants. In the original U.S. Food and Drug Administration ("FDA") Emergency Use Authorization ("EUA") clini

Yahoo | January 14, 2022

LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test

LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue.

Yahoo | January 11, 2022

LumiraDx CRP Test Achieves CE Marking

LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its C-reactive protein (CRP) Test has achieved CE Marking. The LumiraDx CRP Test is a small, portable, fully automated, microfluidic immunoassay test used for the quantitative determination of C-reactive protein with results within four minutes. The measurement of CRP provides important information for the detection and evaluation of infection, and inflammation. In patients with respiratory infection sy

Yahoo | January 11, 2022

LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking

LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its SARS-CoV-2 & Flu A/B Antigen Test has achieved CE Marking. The microfluidic immunofluorescence assay can quickly verify potential infection for patients suspected of influenza and/or COVID-19, helping to identify and differentiate the underlying cause of respiratory illness and to inform treatment decisions at the point of care. Existing respiratory tests on the LumiraDx Platform include the company

Yahoo | December 23, 2021

LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete

LumiraDx (Nasdaq: LMDX) today announced a partnership with digital health non-profit Audere, to offer a self-collected COVID-19 nasal specimen collection kit that has been authorized for use with the LumiraDx SARS-CoV-2 RNA STAR Complete assay to process self-collected samples. Audere's testing solution, [email protected], closely aligns with LumiraDx's continual efforts to increase testing access and support a growing number of testing needs.

Yahoo | December 15, 2021

How Much Of LumiraDx Limited (NASDAQ:LMDX) Do Insiders Own?

Every investor in LumiraDx Limited ( NASDAQ:LMDX ) should be aware of the most powerful shareholder groups. Large...

Yahoo | December 6, 2021

FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions

LumiraDx (Nasdaq: LMDX) announced today that the intended use for its Food and Drug Administration (FDA) Emergency Use Authorization (EUA) SARS-CoV-2 RNA STAR Complete, a rapid, nucleic acid amplification technology for high sensitivity, high throughput COVID-19 testing has been reissued. The EUA now includes (1) testing of asymptomatic individuals, (2) pooling of up to five individuals, (3) access to 384-well configuration on validated open RT-PCR systems and (4) inclusivity of the detection of

Yahoo | December 1, 2021

LumiraDx Reports Third Quarter 2021 Financial Results

LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for the quarter ended September 30, 2021.

Yahoo | November 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4703 seconds.